glp-1 small molecule agonist Oral Small-Molecule Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies In patients with #obesity, incretin-based

These dual RAs are being evaluated mainly in T2D, T1D, overweight/obesity, and few other possible indications (Figure 2)

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin

Obes Surg 29(1):314 AziziKia H et al (2024) Periprocedural changes of serum biomarkers in predicting complications following bariatric surgery for obesity: systematic review and meta-analysis

[DOI] [PMC free article] [PubMed] [Google Scholar] 838.Watson K.T., Wroolie T.E., Tong G., Foland-Ross L.C., Frangou S., Singh M

Excitement has grown in this drug class, with several GLP-1R agonists demonstrating benefit in cardiovascular outcomes studies ( 10 )

Advertising on our site helps support our mission